Drug Trial Radar · NCT01071070
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Jan 26, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
Nov 2009
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
Conditions
- Chronic Kidney Disease
Interventions
paricalcitolDrug
Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Achievement of Two Consecutive Greater Than or Equal to 30% Decreases From Baseline Intact Parathyroid Hormone LevelsTime frame: Baseline to 12 Weeks
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 23483
Beijing, China
Site Reference ID/Investigator# 23485
Beijing, China
Site Reference ID/Investigator# 23482
Beijing, China
Site Reference ID/Investigator# 23484
Dalian, China
Site Reference ID/Investigator# 23486
Guangzhou, China
Site Reference ID/Investigator# 23488
Nanjing, China
Site Reference ID/Investigator# 37722
Qingdao, China
Site Reference ID/Investigator# 23490
Shanghai, China
Site Reference ID/Investigator# 25502
Shanghai, China
Site Reference ID/Investigator# 23489
Shanghai, China
Site Reference ID/Investigator# 23487
Shanghai, China
Site Reference ID/Investigator# 35822
Wenzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.